Shares of Teva Pharmaceutical Industries ( TEVA) rose 5% after the Israeli drugmaker said a U.S. federal court granted its motion for summary judgment in an issue related to its generic version of Merck's ( MRK) Zocor tablets. The matter relates to whether Ivax Diagnostics, which was recently acquired by Teva, is entitled to sell a generic version of the Zocor tablets during an exclusive six-month marketing period. "The Court found unlawful the FDA's October 24, 2005, decision denying Ivax's citizen's petition on the exclusivity issue and, accordingly, has remanded the matter back to the FDA," Teva said in a statement. Shares were trading up $1.88 to $42.38. Other health care volume movers included Pfizer ( PFE), down 19 cents to $25.14; Aetna ( AET), up $1.21 to $39.71; Boston Scientific ( BSX), down 64 cents to $22.60; UnitedHealth Group ( UNH), down 11 cents to $49.63; Generex Biotechnology ( GNBT), up 27 cents to $2.93; Human Genome Sciences ( HGSI), down 16 cents to $11.25; Amgen ( AMGN), down 31 cents to $67.39; Bristol-Myers Squibb ( BMY), down 26 cents to $25.12; Johnson & Johnson ( JNJ), down 1 cent to $58.60; Medtronic ( MDT), down 4 cents to $50.08; Schering-Plough ( SGP), down 15 cents to $19.17.